Institutional investors have queued up to buy stock in Chimeric’s IPO ‘CAR T cell therapy is one of the hottest … Read More
The post Here’s what ASX stockspert Bhavdip143 likes so much about the $35m Chimeric IPO appeared first on Stockhead.
Barry Stroman was a reporter for Zerg Watch, before becoming the lead editor. Barry has previously worked for Wired, MacWorld, PCWorld, and VentureBeat covering countless stories concerning all things related to tech and science. Barry studied at NYU.